Drug intelligence / Profile preview

MRANK-023

Development stage: Preclinical
Lead developer: MindRank
Modality: Small Molecules

Overview

MRANK-023 is a preclinical drug candidate currently under development by MindRank, a biotechnology company leveraging an AI-driven platform for drug discovery. As of the latest company pipeline disclosures, MRANK-023 is in the discovery and optimization stages. The specific biological target, therapeutic indication, and molecular modality for this program remain undisclosed by the developer, though the company primarily focuses on the discovery of small molecule therapeutics.

Beyond the preview

Go deeper on MRANK-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRANK-023.

Explore the full profile